The U.S. FDA has approved Faxitron’s LOCalizer radio frequency identification lesion localization system.
The company in a press release said that other methods for locating non-palpable breast lesions for removal are encumbered by complex regulations, unintended wire migration, potential scheduling conflicts, and added stress for patients. LOCalizer was designed to overcome these complications. A non-radioactive, proprietary Tag, a marker, helps the surgeon remove the right region of breast tissue during a procedure.
Dr. Christine Dauphine, Director, Breast Clinic, said that the technology could accurately measure the distance to target the lesion.
“The most exciting aspect of the LOCalizer technology is being able to accurately measure the distance to the target lesion, something we haven’t been able to do with other localization methods,” says Dr. Christine Dauphine, MD, FACS. “Our team was able to experience the LOCalizer system first-hand in the operating room, and we were thrilled by the prospect of providing patients with a localization method that, by design, could avoid the anxiety of having additional procedures on the day of surgery.”
Product Page: Click here